Format

Send to

Choose Destination
Br J Ophthalmol. 2017 Aug 9. pii: bjophthalmol-2017-310378. doi: 10.1136/bjophthalmol-2017-310378. [Epub ahead of print]

ROCK inhibitors for the treatment of ocular diseases.

Author information

1
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
3
Center for Excellence in Functional and Molecular Imaging, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.
4
Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik am Lindenhofspital, Bern, Switzerland.

Abstract

The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

KEYWORDS:

cornea; glaucoma; neovascularisation; retina; vitreous

Conflict of interest statement

Competing interests: None declared.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center